weight loss at target dose (trial data) ~21% (SURMOUNT) CV risk reduction labelled Under study Format Prefilled KwikPen + single-dose autoinjector India price (May 2026) 14,00027,500/month DCGI-approved Yes (March 2025) Generic competition in India No no Indian biosimilar yet Weight-loss percentages are trial averages at target dose individual response varies
So you need to move around a little bit
Forbes SC, Cox HM (2014) Peptide YY, neuropeptide Y and corticotrophin-releasing factor modulate gastrointestinal motility and food intake during acute stress
Serious adverse events are rare, but ongoing supervision by a healthcare provider familiar with both GLP-1 therapy and PWS is essential
Final Thoughts Before making any definitive decisions, ensure you discuss your options with a licensed healthcare professional who can evaluate whether semaglutide is appropriate for you and, if so, help monitor your situation